FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280583816> ?p ?o ?g. }

• W4280583816 endingPage "982" @default.
• W4280583816 startingPage "982" @default.
• W4280583816 abstract "Clinical trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors improve clinical outcomes in diabetes mellitus (DM) patients. As most studies were performed in Type 2 DM, the cardiovascular effects of SGLT2 inhibition still require clarification in Type 1 DM. We analyzed the effects of SGLT2 inhibitor dapagliflozin on cardiac remodeling in rats with streptozotocin-induced diabetes, an experimental model of Type 1 DM. Methods: Male Wistar rats were assigned into four groups: control (C, n = 14); control treated with dapagliflozin (C + DAPA, n = 14); diabetes (DM, n = 20); and diabetes treated with dapagliflozin (DM + DAPA, n = 20) for 8 weeks. Dapagliflozin dosage was 5 mg/kg/day. Statistical analyses: ANOVA and Tukey or Kruskal−Wallis and Dunn. Results: DM + DAPA presented decreased blood pressure and glycemia and increased body weight compared to DM (C 507 ± 52; C + DAPA 474 ± 50; DM 381 ± 52 *; DM + DAPA 430 ± 48 # g; * p < 0.05 vs. C; # p < 0.05 vs. C + DAPA and DM + DAPA). DM echocardiogram presented left ventricular and left atrium dilation with impaired systolic and diastolic function. Cardiac changes were attenuated by dapagliflozin. Myocardial hydroxyproline concentration and interstitial collagen fraction did not differ between groups. The expression of Type III collagen was lower in DM and DM + DAPA than their controls. Type I collagen expression and Type I-to-III collagen ratio were lower in DM + DAPA than C + DAPA. DM + DAPA had lower lipid hydroperoxide concentration (C 275 ± 42; C + DAPA 299 ± 50; DM 385 ± 54 *; DM + DAPA 304 ± 40 # nmol/g tissue; * p < 0.05 vs. C; # p < 0.05 vs. DM) and higher superoxide dismutase and glutathione peroxidase activity than DM. Advanced glycation end products did not differ between groups. Conclusion: Dapagliflozin is safe, increases body weight, decreases glycemia and oxidative stress, and attenuates cardiac remodeling in an experimental rat model of Type 1 diabetes mellitus." @default.
• W4280583816 created "2022-05-22" @default.
• W4280583816 creator A5028561436 @default.
• W4280583816 creator A5035312159 @default.
• W4280583816 creator A5037305321 @default.
• W4280583816 creator A5043607169 @default.
• W4280583816 creator A5046757573 @default.
• W4280583816 creator A5048629345 @default.
• W4280583816 creator A5053143044 @default.
• W4280583816 creator A5053157812 @default.
• W4280583816 creator A5056013660 @default.
• W4280583816 creator A5082051003 @default.
• W4280583816 creator A5082057062 @default.
• W4280583816 date "2022-05-17" @default.
• W4280583816 modified "2023-10-01" @default.
• W4280583816 title "Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus" @default.
• W4280583816 cites W184858858 @default.
• W4280583816 cites W1890842227 @default.
• W4280583816 cites W1898792314 @default.
• W4280583816 cites W1984311031 @default.
• W4280583816 cites W1990503806 @default.
• W4280583816 cites W1997183104 @default.
• W4280583816 cites W2001895968 @default.
• W4280583816 cites W2011052519 @default.
• W4280583816 cites W2018850789 @default.
• W4280583816 cites W2037940400 @default.
• W4280583816 cites W2069766617 @default.
• W4280583816 cites W2082047957 @default.
• W4280583816 cites W2086779280 @default.
• W4280583816 cites W2093188887 @default.
• W4280583816 cites W2102635112 @default.
• W4280583816 cites W2106826473 @default.
• W4280583816 cites W2109833599 @default.
• W4280583816 cites W2126515213 @default.
• W4280583816 cites W2132250523 @default.
• W4280583816 cites W2140335269 @default.
• W4280583816 cites W2146264128 @default.
• W4280583816 cites W2153249592 @default.
• W4280583816 cites W2154902351 @default.
• W4280583816 cites W2160674153 @default.
• W4280583816 cites W2336688940 @default.
• W4280583816 cites W2337739010 @default.
• W4280583816 cites W2461230463 @default.
• W4280583816 cites W2464450327 @default.
• W4280583816 cites W2469120847 @default.
• W4280583816 cites W2510333739 @default.
• W4280583816 cites W2557156634 @default.
• W4280583816 cites W2594555601 @default.
• W4280583816 cites W2626446274 @default.
• W4280583816 cites W2772333344 @default.
• W4280583816 cites W2775930384 @default.
• W4280583816 cites W2776457178 @default.
• W4280583816 cites W2785186340 @default.
• W4280583816 cites W2785530117 @default.
• W4280583816 cites W2895924902 @default.
• W4280583816 cites W2901096500 @default.
• W4280583816 cites W2937067600 @default.
• W4280583816 cites W2963106552 @default.
• W4280583816 cites W2999431040 @default.
• W4280583816 cites W3003546904 @default.
• W4280583816 cites W3010724393 @default.
• W4280583816 cites W3015077652 @default.
• W4280583816 cites W3016558779 @default.
• W4280583816 cites W3036816724 @default.
• W4280583816 cites W3081324599 @default.
• W4280583816 cites W3086148163 @default.
• W4280583816 cites W3088805960 @default.
• W4280583816 cites W3099218906 @default.
• W4280583816 cites W3107702570 @default.
• W4280583816 cites W3110559523 @default.
• W4280583816 cites W3123572331 @default.
• W4280583816 cites W3131233588 @default.
• W4280583816 cites W3131396654 @default.
• W4280583816 cites W3135579416 @default.
• W4280583816 cites W3138077714 @default.
• W4280583816 cites W3173634910 @default.
• W4280583816 cites W3193297191 @default.
• W4280583816 cites W3194046805 @default.
• W4280583816 cites W3201517494 @default.
• W4280583816 cites W3201729693 @default.
• W4280583816 cites W3205824958 @default.
• W4280583816 cites W3206843611 @default.
• W4280583816 cites W3215582043 @default.
• W4280583816 cites W4200527097 @default.
• W4280583816 cites W4210242902 @default.
• W4280583816 cites W4229519558 @default.
• W4280583816 cites W979426278 @default.
• W4280583816 doi "https://doi.org/10.3390/antiox11050982" @default.
• W4280583816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35624845" @default.
• W4280583816 hasPublicationYear "2022" @default.
• W4280583816 type Work @default.
• W4280583816 citedByCount "4" @default.
• W4280583816 countsByYear W42805838162022 @default.
• W4280583816 countsByYear W42805838162023 @default.
• W4280583816 crossrefType "journal-article" @default.
• W4280583816 hasAuthorship W4280583816A5028561436 @default.
• W4280583816 hasAuthorship W4280583816A5035312159 @default.
• W4280583816 hasAuthorship W4280583816A5037305321 @default.

• next